A Randomized Control trial of Telemedicine vs In Person Oncology Patient Surveillance

This research study is comparing telemedicine and face-to-face visits to understand patients'
experiences with telemedicine versus face to face visits and to understand when it is and is
not appropriate to conduct visits remotely

Inclusion Criteria:

- For breast cancer participants: Early-stage breast cancer defined as Stages I-IIIA at
diagnosis or localized prostate cancer defined as Stages I-III

- For breast cancer participants: participant has completed definitive treatment for
early stage breast cancer including surgery, radiation, chemotherapy, anti-HER2
antibody treatment. Participant may or may not be taking oral anti-estrogen treatment
such as tamoxifen or an aromatase inhibitor

- For prostate cancer participants: participant is on active surveillance or has
undergone definitive surgery for localized prostate cancer

- Participant is on a surveillance follow up visit schedule occurring at every three to
seven month intervals

- Willingness and ability to use Patient Gateway portal

- Participant has access to an electronic device that can support a video and audio
virtual visit platform (for example, laptop computer, desktop computer, smart phone)

- Participants can be women or men

- Age ≥ 18 years

Exclusion Criteria:

- Patients whose next visit requires cytotoxic chemotherapy, radiation therapy,
anti-HER2 antibody therapy or investigational cancer agents are ineligible

- Patients with distant metastatic breast cancer

- Patients with locally advanced or metastatic prostate cancer

- Patients treated by radiation therapy for prostate cancer

- Patients whose next visit requires a prostate biopsy

- Prisoners

- Non-English speaking patients (non-English speaking patients will be excluded from the
trial given the challenges of delivering telemedicine with the use of medical
interpreters. There are also logistical challenges in obtaining the study endpoints,
which are largely survey based, with non-English speakers as well as the possibility
that study endpoints will be influenced by the presence of a medical interpreter
during a visit).